US5519035A - Treatment of stroke or in anticipation of the occurrence of brain ischemia - Google Patents

Treatment of stroke or in anticipation of the occurrence of brain ischemia Download PDF

Info

Publication number
US5519035A
US5519035A US08/084,977 US8497793A US5519035A US 5519035 A US5519035 A US 5519035A US 8497793 A US8497793 A US 8497793A US 5519035 A US5519035 A US 5519035A
Authority
US
United States
Prior art keywords
stroke
administration
protein kinase
sodium nitroprusside
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
US08/084,977
Inventor
Kenneth Maiese
John A. Wagner
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cornell Research Foundation Inc
Original Assignee
Cornell Research Foundation Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cornell Research Foundation Inc filed Critical Cornell Research Foundation Inc
Priority to US08/084,977 priority Critical patent/US5519035A/en
Assigned to CORNELL RESEARCH FOUNDATION, INC. reassignment CORNELL RESEARCH FOUNDATION, INC. ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: MAIESE, KENNETH, WAGNER, JOHN A.
Application granted granted Critical
Publication of US5519035A publication Critical patent/US5519035A/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine

Definitions

  • This invention is directed to reducing the neurological dysfunction normally occurring in a stroke.
  • Strokes are the third largest killer of people in the United States and cost billions of dollars because of lost productivity and the need for rehabilitation. Many of those affected with strokes never recover full neurologic function or even a substantial measure of the neurologic function initially lost.
  • treatment consists of attention to and maintenance of blood pressure and serum glucose, administration of IV fluids and prevention of the occurrence of bed sores.
  • blood thinners such as heparin are administered during the course of a stroke but there is no support for this having any palliative effect.
  • the method comprises administering to the subjects a therapeutically effective amount of a protein kinase C inhibitor, i.e., in the case of those with a stroke an amount of protein kinase C inhibitor which reduces the occurrence of neuronal damage and associated neurological dysfunction that would otherwise occur during a stroke and in the case of those who are of high risk for a stroke an amount of protein kinase C inhibitor which provides an uninterrupted plasma level of protein kinase C inhibitor which on the occurrence of cerebral ischemia will reduce the occurrence of neuronal cell damage and associated neurological dysfunction that would occur during a stroke.
  • a protein kinase C inhibitor i.e., in the case of those with a stroke an amount of protein kinase C inhibitor which reduces the occurrence of neuronal damage and associated neurological dysfunction that would otherwise occur during a stroke and in the case of those who are of high risk for a stroke an amount of protein kinase C inhibitor which provides an uninterrupted plasma level of protein kinase C inhibitor which on the
  • therapy pursuant to the invention very preferably should occur as soon as diagnosis occurs, normally within 6 hours of the onset of the stroke.
  • the administration of the protein kinase C inhibitor should be via a parenteral route and in a neuronal cell protecting amount, i.e., an amount which reduces neuronal cell death compared to that which would occur if the stroke were untreated.
  • a subject who is at high risk for a stroke because of having experienced a previous ischemic event, i.e., a previous transient ischemic attack, a previous residual ischemic neurological deficit or a previous completed stroke or a plurality of these or combinations of these, but who does not currently have a stroke in progress.
  • a previous ischemic event i.e., a previous transient ischemic attack, a previous residual ischemic neurological deficit or a previous completed stroke or a plurality of these or combinations of these, but who does not currently have a stroke in progress.
  • the requirement is to provide a plasma level of protein kinase C inhibitor such that, on the occurrence of cerebral ischemia, there will be sufficient protein kinase C inhibitor already present in the subject to protect neuronal cells, i.e., in an amount which would reduce neuronal cell death compared to that which would occur if a stroke occurred and was untreated.
  • Administration is preferably carried out orally on a daily basis.
  • subject is used herein to mean mammals including humans.
  • the single FIGURE of the drawing is a graph of time of treatment after initiation of conditions functioning as a model for stroke versus cell death for treatment with 10 ⁇ M H-7 in Example II.
  • the method herein comprises administering to a subject currently afflicted with a stroke or previously afflicted with an ischemic event, of a therapeutically effective amount of protein kinase C inhibitor.
  • Suitable protein kinase C inhibitors are those which are non toxic and include, for example, H-7, i.e., 1-(5-isoquinolinylsulfonyl)-2-methylpiperazine, H-8, i.e., N-[2-(methylamine)ethyl]-5-isoquinolinesulfonamide, sphingosine, staurosporine, 1-(5-isoquinolinylsulfonyl)-2,3-dimethylpiperazine, 1-(5-isoquinolinylsulfonyl)-3,5-dimethylpiperazine, N-(2-aminoethyl)-5-isoquinolinesulfonamide, N-(2-guanidinoethyl)-5-isoquinolinesulfonamide and N,N-dimethyl-5-isoquinolinesulfonamide.
  • H-7 i.e., 1-(5-isoquinolinylsulfonyl)
  • H-7 and H-8 are preferred with H-7 being most preferred.
  • H-7 and H-8 are available from Calbiochem (La Jolla, Calif.).
  • Sphingosine and staurosporine are available from Sigma Chemical Company (St. Louis, Mo.). Syntheses for the other listed compounds are described in Hidaka, H., et al, Biochemistry, 23, 5036-5041 (1984).
  • the therapeutically effective amount for those with a stroke is a neuronal cell protecting amount, i.e., an amount which reduces neuronal cell death compared to that which would occur if the stroke were untreated.
  • Cells known to be killed during a stroke include hippocampal neurons, cortical neurons, caudate and putaminol neurons, cerebellar neurons and brain stem neurons. Since, of these, hippocampal neurons are known to be the most sensitive to strokes, the therapeutically effective amount is preferably a hippocampal neuron protecting amount, i.e., an amount which reduces hippocampal neuron death compared to that which would occur if the stroke were untreated.
  • a therapeutically effective amount for those with a stroke is a non toxic amount in the range of 0.005 mg/kg to 100 mg/kg.
  • the dose preferably ranges from 1.5 mg/kg to 25 mg/kg and the very preferred dose normally ranges from 5 mg/kg to 10 mg/kg.
  • Activities for various of the protein kinase C inhibitors are listed in Hidaka, H., et al, Biochemistry, 23, 5036-5041 (1984) and suitable dosages can be determined by multiplying the dosages of H-7 given above by the reciprocal of the relative activity of H-7 to that of the protein kinase C inhibitor for which dosage information is desired.
  • suitable dosages include from 5 to 20 mg/kg and for staurosporine suitable dosages include from 0.005 mg/kg to 1 mg/kg.
  • the therapeutically effective amount for those who are at high risk for a stroke because of having experienced a previous ischemic event but who do not currently have a stroke in progress is one that provides a plasma level of protein kinase C inhibitor such that on occurrence of cerebral ischemia there will be sufficient protein kinase C inhibitor already present in the subject to protect neuronal cells, i.e., in an amount which will reduce neuronal cell death compared to that which would occur if a stroke occurred and was untreated. Since the occurrence of ischemia could come at any time, such plasma level must always be present, that is must be uninterrupted by reduction to a level where sufficient protein kinase C inhibitor is not present to protect neuronal cells from death on the occurrence of ischemia.
  • this plasma level of protein kinase C inhibitor is a non toxic concentration in the range of from about 0.001 ⁇ M to 100 ⁇ M.
  • the amount administered to obtain such plasma level depends on the method of administration and the half-life of the particular protein kinase C inhibitor administered. Preferably, administration is on a daily basis so that each dose can be minimized. For H-7, orally administered, one time a day, a suitable dose might be 20 mg/kg.
  • This can be any method by which the protein kinase C inhibitor crosses the blood-brain barrier in sufficient amount to protect neuronal cells from death. Crossing the blood-brain barrier is typically not a problem for protein kinase C inhibitors as suggested by the pretreatment intraperitoneal administration of H-7 reducing brain edema in an in vivo stroke model (Joo, F., et al, Brain Research, 490, 141-143 (1989).
  • parenteral administration is preferred in order to obtain a fast response, very preferably intravenous or intraarterial administration.
  • administration is preferably carried out orally so that the presence of a health care professional is not required.
  • administration very preferably should occur as soon as diagnosis occurs. Normally, to obtain benefit, administration should be within 6 hours of the onset of the stroke, preferably within 4 hours of the onset of the stroke.
  • administration is preferably on a daily basis for convenience and to minimize the dose at each administration.
  • nitric oxide has been implicated as a mediator of neurodegeneration in vivo models of cerebral ischemia (Nowicki, J. P., et al, Euro, J. Pharm., 204:339-340 (1991)). Furthermore, work by the inventors herein in vitro indicates that hippocampal neuronal death following anoxia is at least in part mediated by nitric oxide, that nitric oxide generated by sodium nitroprusside and by 3-morpholino-sydnonimine was toxic to hippocampal neurons and that it is the nitric oxide from the nitroprusside and not cyanide that causes cell death.
  • the inventors herein have devised a method for the in vitro assessment of potential of drugs for effectiveness in protecting hippocampal neurons from death mediated by the presence of nitric oxide which constitutes an in vitro model for screening drugs for efficacy in protecting neuronal cells from death during cerebral ischemia including strokes.
  • This testing method comprises the steps of forming a culture of neuronal cells in a medium, e.g., 1 ⁇ 10 4 to 1 ⁇ 10 6 cells/mm 2 , administering nitric oxide generating agents (e.g., using a source of nitroprusside or SIN-1 (i.e., 3 -morpholino-sydnonimine)) to the neuronal cells in a fresh culture medium, replacing the culture medium to prevent further nitric oxide administration (e.g., 3 to 15 minutes after nitric oxide administration is initiated), before, at the same time as, and/or after the administering of nitric oxide adding compound to be tested to culture medium containing the cells, and assessing neuronal cell death.
  • a medium e.g., 1 ⁇ 10 4 to 1 ⁇ 10 6 cells/mm 2
  • administering nitric oxide generating agents e.g., using a source of nitroprusside or SIN-1 (i.e., 3 -morpholino-s
  • Hippocampi were obtained from one day old Sprague-Dawley rat pups and maintained by the method described in Furshpan, E. J., et al, Neuron 3:199-207 (1989) except that Sprague-Dawley rats were used instead of Long-Evans rats. Hippocampal sections were then incubated in a solution of papain (10 U/ml), cysteine (3 mmol/1), and dissociation medium for two 20 minutes periods. The hippocampi were then rinsed in dissociation medium and incubated in a solution of trypsin inhibitor (10-20 U/ml) and dissociation medium for three times, 5 min. each.
  • the cells were washed in growth medium three times, two minutes each, and triturated 50 times in two ml of growth medium. The trituration was repeated five times with fresh growth medium to yield a total of 10 ml of cell suspension.
  • Forty milliliters of Opti-MEM-I Gibco BRL, Gaithersburg, Mo.; consisting of a modification of MEM (Eagle's) with HEPES buffer, 2,400 mg/l sodium bicarbonate, hypoxanthine, thymidine, sodium pyruvate, L-glutamine, trace elements and growth factors, and phenol red reduced to 1.6 mg/l
  • Opti-MEM-I Gibco BRL, Gaithersburg, Mo.; consisting of a modification of MEM (Eagle's) with HEPES buffer, 2,400 mg/l sodium bicarbonate, hypoxanthine, thymidine, sodium pyruvate, L-glutamine, trace elements and growth factors, and phenol red reduced to 1.6 mg/l
  • Dissociation medium contained 90 mM Na 2 SO 4 , 30 mM K 2 SO 4 , 5.8 mM MgCl 2 , 0.25 mM CaCl 2 , 10 mM kynurenic acid, and 1 mM HEPES with pH adjusted to 7.4.
  • Growth medium consisted of Leibovitz's L-15 Medium (Gibco BRL, Gaithersburg, Md.) with 6% sterile rat serum (Bioproducts for Science, Indianapolis, Ind.), 150 mM NaHCO 3 , 2.25 mg/ml transferrin, 2.5 ⁇ g/ml insulin, 10 nM progesterone, 90 ⁇ M putrescine, 15 nM selenium, 35 mM glucose, 1 mM L-glutamine, penicillin (50 U/ml), streptomycin (50 ⁇ g/ml), and vitamin mix.
  • the vitamin mix contained L-proline (0.2M), L-cystine (0.025M), p-aminobenzoic acid (7.0 mM), vitamin B-12 (0.3 mM), inositol (11 mM), choline chloride (14.0 mM), fumaric acid (0.04M), coenzyme A (0.1 mM), d-biotin (8 ⁇ M), and DL-6,8-thiotic acid (0.5 mM).
  • Nitric oxide administration was performed by removing the culture medium using a pipette and adding fresh growth medium containing 300 ⁇ M sodium nitroprusside (Sigma Chemicals Company, St. Louis, Mo.). After 5 to 10 minutes the culture medium was replaced with fresh growth medium, and the cultures were placed in a normal oxygen environment, humidified incubator at 37° C. with 5% CO 2 for 24 hours prior to assessing cell death.
  • the compound tested is administered starting before nitric oxide administration, it is also included in the fresh growth medium containing sodium nitroprusside and in the fresh growth medium replacing this. In the case where the compound tested is administered at the same time as nitric oxide is administered, it is later included in the fresh growth medium containing sodium nitroprusside and also in the fresh growth medium replacing this.
  • Hippocampal neuronal cultures were treated with H-7 at doses of 0.001 ⁇ M, 0.01 ⁇ M, 1.0 ⁇ M, 10 ⁇ M and 100 ⁇ M starting one hour prior to exposure to sodium nitroprusside or with no H-7. Without H-7 the neuronal cell survival rate was about 22%. With doses of H-7 of 0.001 ⁇ M, 0.01 ⁇ M and 0.1 ⁇ M, the survival rate increased to about 45%. At doses of 10 ⁇ M and 100 ⁇ M, the survival rate increased to about 63%. Administration of H-7 without nitric oxide showed H-7 was not toxic to the hippocampal cells except at the dose of 100 ⁇ M where survival decreased from 90% to 63%.
  • Hippocampal neuronal cultures were treated with H-7 at doses of 10 ⁇ M, starting 1 hour prior to treatment with sodium nitroprusside, starting at the same time as sodium nitroprusside administration, starting 1 hour after sodium nitroprusside administration, starting 4 hours after sodium nitroprusside administration, starting 6 hours after sodium nitroprusside administration, starting 12 hours after sodium nitroprusside administration and starting 24 hours after sodium nitroprusside administration.
  • administration at the same time as sodium nitroprusside it was also included in the fresh growth medium replacing the culture medium with sodium nitroprusside. Results are shown in the FIGURE of the drawing.
  • neuronal cell survival rate was about 75% compared to about 68% for treatment starting 1 hour after sodium nitroprusside administration (C in the FIGURE of the drawing), about 60% for treatment starting 4 hours after sodium nitroprusside administration (D in the FIGURE of the drawing), about 40% for treatment starting 6 hours after sodium nitroprusside administration (E in the FIGURE of the drawing), about 35% for treatment starting 12 hours after sodium nitroprusside administration (F in the FIGURE of the drawing) and about 22% for treatment starting 24 hours after sodium nitroprusside administration (G in the FIGURE of the drawing) and about 22% where no H-7 is added.
  • Hippocampal neuronal cultures were treated with H-8 at doses of 0.001 ⁇ M, 0.01 ⁇ M, 1.0 ⁇ M, 10 ⁇ M and 100 ⁇ M starting 1 hour prior to exposure to sodium nitroprusside or with no H-8.
  • H-8 was not toxic to the neuronal cells at any of the concentrations. Survival with only administration of sodium nitroprusside (nitric oxide) was 46+2%. Significant protection with H-8 was initially present with doses of 0.01 ⁇ M (60+5% survival) and maximum survival (about 80%) occurred at doses of 10 ⁇ M and greater.
  • Hippocampal neuronal cultures were treated with H-8 at doses of 10 ⁇ M, starting 1 hour prior to treatment with sodium nitroprusside, starting at the same time as sodium nitroprusside administration, starting 1 hour after sodium nitroprusside administration, starting 4 hours after sodium nitroprusside administration, starting 6 hours after sodium nitroprusside administration, starting 12 hours after sodium nitroprusside administration and starting 24 hours after sodium nitroprusside administration. Protection offered was about the same as obtained for H-7 at the same times of administration in Example II as shown in the FIGURE of the drawing.
  • Hippocampal neuronal cultures were treated with D-sphingosine at a dose of 10 ⁇ M starting 1 hour prior to exposure to sodium nitroprusside or with no sphingosine.
  • the sphingosine increased neuronal cell survival from 22% to 45 ⁇ 4%.
  • Hippocampal neuronal cultures were treated with staurosporine at doses of 0.001 ⁇ M, 0.01 ⁇ M, 0.1 ⁇ M and 1.0 ⁇ M.
  • Neuronal cell survival increased from 47+3% in cultures treated only with sodium nitroprusside to about 70% at the doses of 0.01 ⁇ M and 0.1 ⁇ M.
  • survival was about 50%, and at 1 ⁇ M, survival was decreased to 42+3%.
  • Both common carotid arteries are ligated in two groups of female Sprague-Dawley CFY rats. After 10 minutes, ligations are released and reperfusion is allowed.
  • H-7 (20 mg/kg) is administered in the form of a single intraperitoneal injection through a venous catheter 30 minutes after occlusion of the arteries.
  • no therapeutic agent is administered.
  • Histological analysis of stroke volume 24 hours following artery occlusion shows significant reduction in stroke volume for the group administered H-7 compared to the group receiving no treatment.
  • H-8 (20 mg/kg) or D-sphingosine (15 mg/kg) or staurosporine (0.5 mg/kg) is used in place of the H-7, results similar to those obtained with H-7 are obtained.

Abstract

Administration of protein kinase C inhibitors protect neuronal cells from death from cerebral ischemia. Model for screening compounds for potential for protecting neuronal cells from death from cerebral ischemia comprises adding the compounds to medium containing neuronal cells before, at the same time as, and/or after nitric oxide administration.

Description

This invention was made at least in part with Government support under Grants NINDS K08-NS-01599 and NEI EY0654, from the National Institutes of Health.
TECHNICAL FIELD
This invention is directed to reducing the neurological dysfunction normally occurring in a stroke.
BACKGROUND OF THE INVENTION
Strokes are the third largest killer of people in the United States and cost billions of dollars because of lost productivity and the need for rehabilitation. Many of those affected with strokes never recover full neurologic function or even a substantial measure of the neurologic function initially lost.
Presently, treatment consists of attention to and maintenance of blood pressure and serum glucose, administration of IV fluids and prevention of the occurrence of bed sores. Sometimes blood thinners such as heparin are administered during the course of a stroke but there is no support for this having any palliative effect.
SUMMARY OF THE INVENTION
It is an object of the invention herein to provide a method of treating subjects with strokes or who are of high risk for a stroke because of having experienced a previous ischemic event, to reduce the occurrence of neuronal damage and associated neurological dysfunction in a stroke compared to that which normally occurs. The method comprises administering to the subjects a therapeutically effective amount of a protein kinase C inhibitor, i.e., in the case of those with a stroke an amount of protein kinase C inhibitor which reduces the occurrence of neuronal damage and associated neurological dysfunction that would otherwise occur during a stroke and in the case of those who are of high risk for a stroke an amount of protein kinase C inhibitor which provides an uninterrupted plasma level of protein kinase C inhibitor which on the occurrence of cerebral ischemia will reduce the occurrence of neuronal cell damage and associated neurological dysfunction that would occur during a stroke.
We turn firstly to the case of a subject currently afflicted with a stroke. For such subject, therapy pursuant to the invention very preferably should occur as soon as diagnosis occurs, normally within 6 hours of the onset of the stroke. In order to obtain the fastest response, the administration of the protein kinase C inhibitor should be via a parenteral route and in a neuronal cell protecting amount, i.e., an amount which reduces neuronal cell death compared to that which would occur if the stroke were untreated.
We turn now to the case of a subject who is at high risk for a stroke because of having experienced a previous ischemic event, i.e., a previous transient ischemic attack, a previous residual ischemic neurological deficit or a previous completed stroke or a plurality of these or combinations of these, but who does not currently have a stroke in progress. For such subject, the requirement is to provide a plasma level of protein kinase C inhibitor such that, on the occurrence of cerebral ischemia, there will be sufficient protein kinase C inhibitor already present in the subject to protect neuronal cells, i.e., in an amount which would reduce neuronal cell death compared to that which would occur if a stroke occurred and was untreated. Administration is preferably carried out orally on a daily basis.
The term "subject" is used herein to mean mammals including humans.
BRIEF DESCRIPTION OF THE DRAWING
The single FIGURE of the drawing is a graph of time of treatment after initiation of conditions functioning as a model for stroke versus cell death for treatment with 10 μM H-7 in Example II.
DETAILED DESCRIPTION
As indicated above, the method herein comprises administering to a subject currently afflicted with a stroke or previously afflicted with an ischemic event, of a therapeutically effective amount of protein kinase C inhibitor.
Suitable protein kinase C inhibitors are those which are non toxic and include, for example, H-7, i.e., 1-(5-isoquinolinylsulfonyl)-2-methylpiperazine, H-8, i.e., N-[2-(methylamine)ethyl]-5-isoquinolinesulfonamide, sphingosine, staurosporine, 1-(5-isoquinolinylsulfonyl)-2,3-dimethylpiperazine, 1-(5-isoquinolinylsulfonyl)-3,5-dimethylpiperazine, N-(2-aminoethyl)-5-isoquinolinesulfonamide, N-(2-guanidinoethyl)-5-isoquinolinesulfonamide and N,N-dimethyl-5-isoquinolinesulfonamide. H-7 and H-8 are preferred with H-7 being most preferred. H-7 and H-8 are available from Calbiochem (La Jolla, Calif.). Sphingosine and staurosporine are available from Sigma Chemical Company (St. Louis, Mo.). Syntheses for the other listed compounds are described in Hidaka, H., et al, Biochemistry, 23, 5036-5041 (1984).
The therapeutically effective amount for those with a stroke is a neuronal cell protecting amount, i.e., an amount which reduces neuronal cell death compared to that which would occur if the stroke were untreated. Cells known to be killed during a stroke include hippocampal neurons, cortical neurons, caudate and putaminol neurons, cerebellar neurons and brain stem neurons. Since, of these, hippocampal neurons are known to be the most sensitive to strokes, the therapeutically effective amount is preferably a hippocampal neuron protecting amount, i.e., an amount which reduces hippocampal neuron death compared to that which would occur if the stroke were untreated. In general a therapeutically effective amount for those with a stroke is a non toxic amount in the range of 0.005 mg/kg to 100 mg/kg. For H-7, the dose preferably ranges from 1.5 mg/kg to 25 mg/kg and the very preferred dose normally ranges from 5 mg/kg to 10 mg/kg. Activities for various of the protein kinase C inhibitors are listed in Hidaka, H., et al, Biochemistry, 23, 5036-5041 (1984) and suitable dosages can be determined by multiplying the dosages of H-7 given above by the reciprocal of the relative activity of H-7 to that of the protein kinase C inhibitor for which dosage information is desired. For sphingosine, suitable dosages include from 5 to 20 mg/kg and for staurosporine suitable dosages include from 0.005 mg/kg to 1 mg/kg.
The therapeutically effective amount for those who are at high risk for a stroke because of having experienced a previous ischemic event but who do not currently have a stroke in progress, is one that provides a plasma level of protein kinase C inhibitor such that on occurrence of cerebral ischemia there will be sufficient protein kinase C inhibitor already present in the subject to protect neuronal cells, i.e., in an amount which will reduce neuronal cell death compared to that which would occur if a stroke occurred and was untreated. Since the occurrence of ischemia could come at any time, such plasma level must always be present, that is must be uninterrupted by reduction to a level where sufficient protein kinase C inhibitor is not present to protect neuronal cells from death on the occurrence of ischemia. In general, this plasma level of protein kinase C inhibitor is a non toxic concentration in the range of from about 0.001 μM to 100 μM. The amount administered to obtain such plasma level depends on the method of administration and the half-life of the particular protein kinase C inhibitor administered. Preferably, administration is on a daily basis so that each dose can be minimized. For H-7, orally administered, one time a day, a suitable dose might be 20 mg/kg.
We turn now to the methods of administration. This can be any method by which the protein kinase C inhibitor crosses the blood-brain barrier in sufficient amount to protect neuronal cells from death. Crossing the blood-brain barrier is typically not a problem for protein kinase C inhibitors as suggested by the pretreatment intraperitoneal administration of H-7 reducing brain edema in an in vivo stroke model (Joo, F., et al, Brain Research, 490, 141-143 (1989). For the case of a subject currently afflicted with a stroke in progress, parenteral administration is preferred in order to obtain a fast response, very preferably intravenous or intraarterial administration. For the case of a subject who is at high risk for a stroke because of having experienced a previous ischemic event but who does not currently have a stroke in progress, administration is preferably carried out orally so that the presence of a health care professional is not required.
We turn now to the time of administration. We turn firstly to those subjects with a stroke in progress. For those with a stroke, time is of the essence so administration very preferably should occur as soon as diagnosis occurs. Normally, to obtain benefit, administration should be within 6 hours of the onset of the stroke, preferably within 4 hours of the onset of the stroke. We turn now to those subjects who are at high risk for a stroke because of having experienced a previous ischemic event but who do not currently have a stroke in progress; administration is preferably on a daily basis for convenience and to minimize the dose at each administration.
We turn now to examples which illustrate the efficacy of the invention.
It is noted that nitric oxide has been implicated as a mediator of neurodegeneration in vivo models of cerebral ischemia (Nowicki, J. P., et al, Euro, J. Pharm., 204:339-340 (1991)). Furthermore, work by the inventors herein in vitro indicates that hippocampal neuronal death following anoxia is at least in part mediated by nitric oxide, that nitric oxide generated by sodium nitroprusside and by 3-morpholino-sydnonimine was toxic to hippocampal neurons and that it is the nitric oxide from the nitroprusside and not cyanide that causes cell death. On this basis, the inventors herein have devised a method for the in vitro assessment of potential of drugs for effectiveness in protecting hippocampal neurons from death mediated by the presence of nitric oxide which constitutes an in vitro model for screening drugs for efficacy in protecting neuronal cells from death during cerebral ischemia including strokes. This testing method comprises the steps of forming a culture of neuronal cells in a medium, e.g., 1×104 to 1×106 cells/mm2, administering nitric oxide generating agents (e.g., using a source of nitroprusside or SIN-1 (i.e., 3 -morpholino-sydnonimine)) to the neuronal cells in a fresh culture medium, replacing the culture medium to prevent further nitric oxide administration (e.g., 3 to 15 minutes after nitric oxide administration is initiated), before, at the same time as, and/or after the administering of nitric oxide adding compound to be tested to culture medium containing the cells, and assessing neuronal cell death.
In examples, compounds were evaluated for protecting neuronal cells from death during cerebral ischemia by the specific execution of said testing method which is set forth below.
Hippocampi were obtained from one day old Sprague-Dawley rat pups and maintained by the method described in Furshpan, E. J., et al, Neuron 3:199-207 (1989) except that Sprague-Dawley rats were used instead of Long-Evans rats. Hippocampal sections were then incubated in a solution of papain (10 U/ml), cysteine (3 mmol/1), and dissociation medium for two 20 minutes periods. The hippocampi were then rinsed in dissociation medium and incubated in a solution of trypsin inhibitor (10-20 U/ml) and dissociation medium for three times, 5 min. each. The cells were washed in growth medium three times, two minutes each, and triturated 50 times in two ml of growth medium. The trituration was repeated five times with fresh growth medium to yield a total of 10 ml of cell suspension. Forty milliliters of Opti-MEM-I (Gibco BRL, Gaithersburg, Mo.; consisting of a modification of MEM (Eagle's) with HEPES buffer, 2,400 mg/l sodium bicarbonate, hypoxanthine, thymidine, sodium pyruvate, L-glutamine, trace elements and growth factors, and phenol red reduced to 1.6 mg/l) was added to this cell suspension and the dissociated cells were plated at a density of approximately 15×105 cells/mm2 in 35 mm2 polylysine-laminin coated plates (Falcon Labware, Lincoln Park, N.J.). Cells were maintained in growth medium at 37° C. in a humidified atmosphere of 5% CO2 and 95% room air. Following a two hour incubation period to allow for cell adhesion, culture medium was replaced with 1.5 ml of growth medium and the medium was subsequently replaced weekly. All experiments were performed with cultured neurons that had been in culture for two to three weeks. Non-neuronal cells, which were identified by morphology, accounted for less than 20% of the total cell population.
Dissociation medium contained 90 mM Na2 SO4, 30 mM K2 SO4, 5.8 mM MgCl2, 0.25 mM CaCl2, 10 mM kynurenic acid, and 1 mM HEPES with pH adjusted to 7.4. Growth medium consisted of Leibovitz's L-15 Medium (Gibco BRL, Gaithersburg, Md.) with 6% sterile rat serum (Bioproducts for Science, Indianapolis, Ind.), 150 mM NaHCO3, 2.25 mg/ml transferrin, 2.5 μg/ml insulin, 10 nM progesterone, 90 μM putrescine, 15 nM selenium, 35 mM glucose, 1 mM L-glutamine, penicillin (50 U/ml), streptomycin (50 μg/ml), and vitamin mix. The vitamin mix contained L-proline (0.2M), L-cystine (0.025M), p-aminobenzoic acid (7.0 mM), vitamin B-12 (0.3 mM), inositol (11 mM), choline chloride (14.0 mM), fumaric acid (0.04M), coenzyme A (0.1 mM), d-biotin (8 μM), and DL-6,8-thiotic acid (0.5 mM).
Nitric oxide administration was performed by removing the culture medium using a pipette and adding fresh growth medium containing 300 μM sodium nitroprusside (Sigma Chemicals Company, St. Louis, Mo.). After 5 to 10 minutes the culture medium was replaced with fresh growth medium, and the cultures were placed in a normal oxygen environment, humidified incubator at 37° C. with 5% CO2 for 24 hours prior to assessing cell death.
In the case where the compound tested is administered starting before nitric oxide administration, it is also included in the fresh growth medium containing sodium nitroprusside and in the fresh growth medium replacing this. In the case where the compound tested is administered at the same time as nitric oxide is administered, it is later included in the fresh growth medium containing sodium nitroprusside and also in the fresh growth medium replacing this.
Hippocampal neuronal injury was determined by bright field microscopy using a 0.4% trypan blue dye exclusion method 24 hours following treatment with nitric oxide. Neurons were identified by morphology. The mean survival was determined by counting 8 randomly selected non-overlapping fields with approximately 10-20 neurons (viable+non-viable) in each 35 mm petri dish. The mean survival from each culture dish represents an N=1 determination. Each experiment was replicated 3-5 times independently on separate occasions with different cultures.
We turn now to the examples relying on this in vitro method to show efficacy for protein kinase C inhibitors in the treatment method herein.
EXAMPLE I
Hippocampal neuronal cultures were treated with H-7 at doses of 0.001 μM, 0.01 μM, 1.0 μM, 10 μM and 100 μM starting one hour prior to exposure to sodium nitroprusside or with no H-7. Without H-7 the neuronal cell survival rate was about 22%. With doses of H-7 of 0.001 μM, 0.01 μM and 0.1 μM, the survival rate increased to about 45%. At doses of 10 μM and 100 μM, the survival rate increased to about 63%. Administration of H-7 without nitric oxide showed H-7 was not toxic to the hippocampal cells except at the dose of 100 μM where survival decreased from 90% to 63%.
EXAMPLE II
Hippocampal neuronal cultures were treated with H-7 at doses of 10 μM, starting 1 hour prior to treatment with sodium nitroprusside, starting at the same time as sodium nitroprusside administration, starting 1 hour after sodium nitroprusside administration, starting 4 hours after sodium nitroprusside administration, starting 6 hours after sodium nitroprusside administration, starting 12 hours after sodium nitroprusside administration and starting 24 hours after sodium nitroprusside administration. In the case of administration at the same time as sodium nitroprusside, it was also included in the fresh growth medium replacing the culture medium with sodium nitroprusside. Results are shown in the FIGURE of the drawing. For treatment starting 1 hour before (A in the FIGURE of the drawing) and treatment starting at the same time as sodium nitroprusside administration (B in the FIGURE of the drawing), neuronal cell survival rate was about 75% compared to about 68% for treatment starting 1 hour after sodium nitroprusside administration (C in the FIGURE of the drawing), about 60% for treatment starting 4 hours after sodium nitroprusside administration (D in the FIGURE of the drawing), about 40% for treatment starting 6 hours after sodium nitroprusside administration (E in the FIGURE of the drawing), about 35% for treatment starting 12 hours after sodium nitroprusside administration (F in the FIGURE of the drawing) and about 22% for treatment starting 24 hours after sodium nitroprusside administration (G in the FIGURE of the drawing) and about 22% where no H-7 is added.
EXAMPLE III
Hippocampal neuronal cultures were treated with H-8 at doses of 0.001 μM, 0.01 μM, 1.0 μM, 10 μM and 100 μM starting 1 hour prior to exposure to sodium nitroprusside or with no H-8. H-8 was not toxic to the neuronal cells at any of the concentrations. Survival with only administration of sodium nitroprusside (nitric oxide) was 46+2%. Significant protection with H-8 was initially present with doses of 0.01 μM (60+5% survival) and maximum survival (about 80%) occurred at doses of 10 μM and greater.
EXAMPLE IV
Hippocampal neuronal cultures were treated with H-8 at doses of 10 μM, starting 1 hour prior to treatment with sodium nitroprusside, starting at the same time as sodium nitroprusside administration, starting 1 hour after sodium nitroprusside administration, starting 4 hours after sodium nitroprusside administration, starting 6 hours after sodium nitroprusside administration, starting 12 hours after sodium nitroprusside administration and starting 24 hours after sodium nitroprusside administration. Protection offered was about the same as obtained for H-7 at the same times of administration in Example II as shown in the FIGURE of the drawing.
EXAMPLE V
Hippocampal neuronal cultures were treated with D-sphingosine at a dose of 10 μM starting 1 hour prior to exposure to sodium nitroprusside or with no sphingosine. The sphingosine increased neuronal cell survival from 22% to 45±4%.
EXAMPLE VI
Hippocampal neuronal cultures were treated with staurosporine at doses of 0.001 μM, 0.01 μM, 0.1 μM and 1.0 μM. Neuronal cell survival increased from 47+3% in cultures treated only with sodium nitroprusside to about 70% at the doses of 0.01 μM and 0.1 μM. At 0.001 μM, survival was about 50%, and at 1 μM, survival was decreased to 42+3%.
EXAMPLE VII
Both common carotid arteries are ligated in two groups of female Sprague-Dawley CFY rats. After 10 minutes, ligations are released and reperfusion is allowed.
In the case of one group, H-7 (20 mg/kg) is administered in the form of a single intraperitoneal injection through a venous catheter 30 minutes after occlusion of the arteries. In the case of the other group, no therapeutic agent is administered.
Histological analysis of stroke volume 24 hours following artery occlusion shows significant reduction in stroke volume for the group administered H-7 compared to the group receiving no treatment.
When H-8 (20 mg/kg) or D-sphingosine (15 mg/kg) or staurosporine (0.5 mg/kg) is used in place of the H-7, results similar to those obtained with H-7 are obtained.
Variations will be obvious to those skilled in the art. Therefore, the invention is definitely the scope of the claims.

Claims (5)

What is claimed is:
1. A method of treatment of a subject with a stroke in progress to reduce the occurrence of neuronal damage, said method comprising administering to said subject within 6 hours of the onset of the stroke a neuronal cell protecting amount of a protein kinase C inhibitor.
2. A method of treatment of a subject with a stroke in progress to reduce the occurrence of neuronal damage, said method comprising administering to said subject within 6 hours of the onset of the stroke a neuronal cell protecting amount of a protein kinase C inhibitor selected from the group consisting of H-7 and H-8.
3. The method of claim 2 wherein, the administering is via a parenteral route.
4. The method of claim 3 wherein the protein kinase C inhibitor is H-7.
5. The method of claim 3 wherein the protein kinase C inhibitor is H-8.
US08/084,977 1993-07-02 1993-07-02 Treatment of stroke or in anticipation of the occurrence of brain ischemia Expired - Fee Related US5519035A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US08/084,977 US5519035A (en) 1993-07-02 1993-07-02 Treatment of stroke or in anticipation of the occurrence of brain ischemia

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US08/084,977 US5519035A (en) 1993-07-02 1993-07-02 Treatment of stroke or in anticipation of the occurrence of brain ischemia

Publications (1)

Publication Number Publication Date
US5519035A true US5519035A (en) 1996-05-21

Family

ID=22188405

Family Applications (1)

Application Number Title Priority Date Filing Date
US08/084,977 Expired - Fee Related US5519035A (en) 1993-07-02 1993-07-02 Treatment of stroke or in anticipation of the occurrence of brain ischemia

Country Status (1)

Country Link
US (1) US5519035A (en)

Cited By (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998014186A1 (en) * 1996-09-30 1998-04-09 Eisai Co., Limited Substances and their uses
US5785993A (en) * 1995-03-24 1998-07-28 Focal, Inc. Reduction of adhesions using controlled delivery of active oxygen inhibitors
WO1999000117A2 (en) * 1997-06-27 1999-01-07 Ontogeny, Inc. Neuroprotective methods and reagents
WO1999004775A2 (en) * 1997-07-24 1999-02-04 Ontogeny, Inc. Method of treating dopaminergic and gaba-nergic disorders
US5914345A (en) * 1994-10-11 1999-06-22 Endoluminal Therapeutics, Inc. Treatment of tissues to reduce subsequent response to injury
WO1999047153A2 (en) * 1998-03-19 1999-09-23 Brigham & Women's Hospital, Inc. UPREGULATION OF TYPE III ENDOTHELIAL CELL NITRIC OXIDE SYNTHASE BY rho GTPase FUNCTION INHIBITORS
WO2000003746A2 (en) * 1998-07-14 2000-01-27 The Brigham And Women's Hospital, Inc. Upregulation of type iii endothelial cell nitric oxide synthase by agents that disrupt actin cytoskeletal organization
US6147109A (en) * 1997-10-14 2000-11-14 The General Hospital Corporation Upregulation of Type III endothelial cell Nitric Oxide Synthase by HMG-CoA reductase inhibitors
US6423751B1 (en) * 1998-07-14 2002-07-23 The Brigham And Women's Hospital, Inc. Upregulation of type III endothelial cell nitric oxide synthase by agents that disrupt actin cytoskeletal organization
US6639051B2 (en) 1997-10-20 2003-10-28 Curis, Inc. Regulation of epithelial tissue by hedgehog-like polypeptides, and formulations and uses related thereto
US20030212079A1 (en) * 2000-08-08 2003-11-13 Grant Elfrida R. 4-pyrimidinamine derivatives, pharmaceutical compositions and related methods
US20030225085A1 (en) * 2000-08-08 2003-12-04 Grant Elfrida R. 2-pyridinamine compositions and related methods
US20050203092A1 (en) * 2000-08-08 2005-09-15 Benjamin Elfrida R. 4-Pyrimidinamine derivatives, pharmaceutical compositions and related methods
DE102004019413A1 (en) * 2004-04-19 2005-11-24 Phenos Gmbh Use of substances (e.g. nucleic acids, proteins and peptides), which restrain/reduce the expression and/or activity of protein kinase C-epsilon for the treatment/prevention of e.g. circulatory and vascular diseases
US20060020020A1 (en) * 1999-01-13 2006-01-26 Curis, Inc. Regulators of the hedgehog pathway, compositions and uses related thereto
DE102008029072A1 (en) * 2008-06-10 2009-12-17 Lang, Florian, Prof. Dr.med. Substance, which inhibits serum and glucocorticoid dependent kinase 3, useful for the prophylaxis and/or treatment or diagnosis of age-related diseases e.g. arteriosclerosis, skin atrophy, myasthenia, infertility, stroke and kyphosis
US20150133405A1 (en) * 2012-05-08 2015-05-14 Aeromics, Llc Methods
US9827253B2 (en) 2013-11-06 2017-11-28 Aeromics, Inc. Prodrug salts

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4940694A (en) * 1985-02-18 1990-07-10 Fidia, S.P.A. Therapeutic use of GM1 in severe cerebral ischemic strokes pathologies
EP0446699A1 (en) * 1990-02-26 1991-09-18 Merrell Pharmaceuticals Inc. Inhibitors of nitric oxide biosynthesis
US5204370A (en) * 1990-11-05 1993-04-20 Sphinx Pharmaceuticals Corporation Bis-(hydroxyalkylamino)-anthraquinone inhibitors of protein kinase C
US5266594A (en) * 1992-05-12 1993-11-30 Dawson Valina L Inhibitors of nitric oxide synthase and use thereof to prevent glutamate neurotoxicity
US5344841A (en) * 1990-11-02 1994-09-06 Sphinx Pharmaceuticals Corporation Bis-(hydroxylakylamino)-anthraquinone inhibitors of protein kinase C

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4940694A (en) * 1985-02-18 1990-07-10 Fidia, S.P.A. Therapeutic use of GM1 in severe cerebral ischemic strokes pathologies
EP0446699A1 (en) * 1990-02-26 1991-09-18 Merrell Pharmaceuticals Inc. Inhibitors of nitric oxide biosynthesis
US5344841A (en) * 1990-11-02 1994-09-06 Sphinx Pharmaceuticals Corporation Bis-(hydroxylakylamino)-anthraquinone inhibitors of protein kinase C
US5204370A (en) * 1990-11-05 1993-04-20 Sphinx Pharmaceuticals Corporation Bis-(hydroxyalkylamino)-anthraquinone inhibitors of protein kinase C
US5266594A (en) * 1992-05-12 1993-11-30 Dawson Valina L Inhibitors of nitric oxide synthase and use thereof to prevent glutamate neurotoxicity

Non-Patent Citations (54)

* Cited by examiner, † Cited by third party
Title
AN 111:90221. Joo, F., et al, "Inhibition by H-7 of the Protein Kinese C Prevents Formation of Brain Edema in Sprague-Dawley CFY rats", Brain Research (1989), 490(1), 141-143.
AN 111:90221. Joo, F., et al, Inhibition by H 7 of the Protein Kinese C Prevents Formation of Brain Edema in Sprague Dawley CFY rats , Brain Research (1989), 490(1), 141 143. *
Bredt, D. S., et al, Proc. Natl. Acad. Sci. USA, vol. 86, 9030 9033, Nov. 1989. *
Bredt, D. S., et al, Proc. Natl. Acad. Sci. USA, vol. 86, 9030-9033, Nov. 1989.
Bredt, D. S., et al, The Journal of Biological Chemistry, vol. 267, No. 16, 10976 10981, Jun. 1992. *
Bredt, D. S., et al, The Journal of Biological Chemistry, vol. 267, No. 16, 10976-10981, Jun. 1992.
Dawson, V. L., et al, Proc. Natl. Acad. Sci, USA 88, 6368 6371 (1991). *
Dawson, V. L., et al, Proc. Natl. Acad. Sci, USA 88, 6368-6371 (1991).
Endoh, M., et al, Neuroscience letters 154, 125 128 (1993). *
Endoh, M., et al, Neuroscience letters 154, 125-128 (1993).
Favaron, M., et al, Proc. Natl. Acad. Sci. USA 85, 7351 7355 (Oct. 1988). *
Favaron, M., et al, Proc. Natl. Acad. Sci. USA 85, 7351-7355 (Oct. 1988).
Favaron, M., et al, Proc. Natl. Acad. Sci. USA, vol. 87, 1938 1987, Mar. 1990. *
Favaron, M., et al, Proc. Natl. Acad. Sci. USA, vol. 87, 1938-1987, Mar. 1990.
Garthwaite, J., et al, European Journal of Pharmacology Molecular Pharmacology Section, 172, 413 416 (1989). *
Garthwaite, J., et al, European Journal of Pharmacology--Molecular Pharmacology Section, 172, 413-416 (1989).
Hannun, Y. A., et al, J. Biol. Chem., 261, 12604 12609 (1986). *
Hannun, Y. A., et al, J. Biol. Chem., 261, 12604-12609 (1986).
Hara, H., et al, "Staurosporine, a Novel Protein Kinase C Inhibitor, Prevents Neuronal Damage in the Gerbil and Rat", J. Cereb. Blood Flow Metab. (1990), 10(5), 646-653, Chem. Abstract AN 114:480 CA.
Hara, H., et al, Staurosporine, a Novel Protein Kinase C Inhibitor, Prevents Neuronal Damage in the Gerbil and Rat , J. Cereb. Blood Flow Metab. (1990), 10(5), 646 653, Chem. Abstract AN 114:480 CA. *
Hidaka, H., et al, Biochemistry, 23, 5036 5041, 1984. *
Hidaka, H., et al, Biochemistry, 23, 5036-5041, 1984.
Kawamoto, S., et al, Biochem. Biophys. Res. Commun. 125, 258 264 (1984). *
Kawamoto, S., et al, Biochem. Biophys. Res. Commun. 125, 258-264 (1984).
Knowles, R. G., et al, Biochem J., 269: 207 210 (1990). *
Knowles, R. G., et al, Biochem J., 269: 207-210 (1990).
Knowles, R. G., Proc. Natl. Acad. Sci. USA, vol 86, 5159 5162, Jul. 1989. *
Knowles, R. G., Proc. Natl. Acad. Sci. USA, vol 86, 5159-5162, Jul. 1989.
Lancaster, J. R., American Scientist, 80, 248 257 (May Jun. 1992). *
Lancaster, J. R., American Scientist, 80, 248-257 (May-Jun. 1992).
Maiese, K., et al, Presentation at International Meeting on Microcirculatory Stasis, Tokyo, Japan, May 20, 1993, entitled "Down-Regulation of Protein Kinase C is Neuroprotective During Nitric Oxide Toxicity".
Maiese, K., et al, Presentation at International Meeting on Microcirculatory Stasis, Tokyo, Japan, May 20, 1993, entitled Down Regulation of Protein Kinase C is Neuroprotective During Nitric Oxide Toxicity . *
Maiese, K., et al, Soc. Neurosci. Abst., 18(2), 1453, presented Oct. 30, 1992. *
Mattson et al, M. P., et al, The Journal of Neuroscience, 8(6), 1087 2100 (Jun. 1988). *
Mattson et al, M. P., et al, The Journal of Neuroscience, 8(6), 1087-2100 (Jun. 1988).
Mattson M., Experimental Neurology, 112, 95 103 (1991). *
Mattson M., Experimental Neurology, 112, 95-103 (1991).
McKenna et al, U.S. Statutory Invention Registration H1168, published Apr. 6, 1993. *
Nakane, M., et al, Biochem. Biophys. Res. Commun, 180, 1396 1402, Nov. 1991. *
Nakane, M., et al, Biochem. Biophys. Res. Commun, 180, 1396-1402, Nov. 1991.
Nixon, J. S., et al, Agents and Actions, 32, 3/4, 188 193 (1991). *
Nixon, J. S., et al, Agents and Actions, 32, 3/4, 188-193 (1991).
Nowicki, J. P., et al, Euro. J. Pharm. 204, 339 340 (1991). *
Nowicki, J. P., et al, Euro. J. Pharm. 204, 339-340 (1991).
Ohono et al, "Effect of Staurosporine, a PKC Inhibitor, on Impairment of Working Memory in Rats Exposed to Cerebral Ischemia", Eur. J. Pharm 29 Oct. 1991 204(1) 113-6. AN 92209620.
Ohono et al, Effect of Staurosporine, a PKC Inhibitor, on Impairment of Working Memory in Rats Exposed to Cerebral Ischemia , Eur. J. Pharm 29 Oct. 1991 204(1) 113 6. AN 92209620. *
Program for International Meeting on Microcirculatory Stasis in the Brain, Tokyo, Japan, May 20 21, 1993. *
Program for International Meeting on Microcirculatory Stasis in the Brain, Tokyo, Japan, May 20-21, 1993.
Program for International Symposium on Cerebral Blood Vessel 93, Mt. Zao, Japan, May 28 30, 1993. *
Program for International Symposium on Cerebral Blood Vessel '93, Mt. Zao, Japan, May 28-30, 1993.
Rothman, S. M., et al, Annals of Neurology, vol. 19, No. 2, Feb. 1986, pp. 105 111. *
Rothman, S. M., et al, Annals of Neurology, vol. 19, No. 2, Feb. 1986, pp. 105-111.
Sato, S., Biochimica et Biophysica Acta, 1181, 195 197 (1993). *
Sato, S., Biochimica et Biophysica Acta, 1181, 195-197 (1993).

Cited By (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6071956A (en) * 1994-10-11 2000-06-06 Endoluminal Therapeutics, Inc. Treatment of tissues to reduce subsequent response to injury
US5914345A (en) * 1994-10-11 1999-06-22 Endoluminal Therapeutics, Inc. Treatment of tissues to reduce subsequent response to injury
US5785993A (en) * 1995-03-24 1998-07-28 Focal, Inc. Reduction of adhesions using controlled delivery of active oxygen inhibitors
WO1998014186A1 (en) * 1996-09-30 1998-04-09 Eisai Co., Limited Substances and their uses
US20020142943A1 (en) * 1996-09-30 2002-10-03 Eisai Co., Limited Modifying the permeability of physiological barriers
US6407058B1 (en) 1996-09-30 2002-06-18 Eisai Co., Limited Modifying the permeability of physiological barriers
US20100144616A1 (en) * 1997-06-27 2010-06-10 Curis, Inc. Neuroprotective methods and reagents
US6767888B1 (en) 1997-06-27 2004-07-27 Curis, Inc. Neuroprotective methods and reagents
US20040235739A1 (en) * 1997-06-27 2004-11-25 Curis, Inc. Neuroprotective methods and reagents
WO1999000117A2 (en) * 1997-06-27 1999-01-07 Ontogeny, Inc. Neuroprotective methods and reagents
WO1999000117A3 (en) * 1997-06-27 1999-04-01 Ontogeny Inc Neuroprotective methods and reagents
US7144997B2 (en) 1997-07-24 2006-12-05 Curis, Inc. Vertebrate embryonic patterning-inducing proteins, compositions and uses related therto
WO1999004775A3 (en) * 1997-07-24 2000-11-23 Ontogeny Inc Method of treating dopaminergic and gaba-nergic disorders
US20070048286A1 (en) * 1997-07-24 2007-03-01 Ningning Miao Method of treating dopaminergic and GABA-nergic disorders
US7138492B2 (en) 1997-07-24 2006-11-21 Curis, Inc. Method of treating dopaminergic and GABA-nergic disorders
WO1999004775A2 (en) * 1997-07-24 1999-02-04 Ontogeny, Inc. Method of treating dopaminergic and gaba-nergic disorders
US6147109A (en) * 1997-10-14 2000-11-14 The General Hospital Corporation Upregulation of Type III endothelial cell Nitric Oxide Synthase by HMG-CoA reductase inhibitors
US6639051B2 (en) 1997-10-20 2003-10-28 Curis, Inc. Regulation of epithelial tissue by hedgehog-like polypeptides, and formulations and uses related thereto
US20070110698A1 (en) * 1997-10-20 2007-05-17 Wang Elizabeth A Regulation of epithelial tissue by hedgehog-like polypeptides, and formulations and uses related thereto
US20090118187A1 (en) * 1997-10-20 2009-05-07 Wang Elizabeth A Regulation of epithelial tissue by hedgehog-like polypeptides, and formulations and uses related thereto
WO1999047153A3 (en) * 1998-03-19 1999-11-18 Brigham & Womens Hospital UPREGULATION OF TYPE III ENDOTHELIAL CELL NITRIC OXIDE SYNTHASE BY rho GTPase FUNCTION INHIBITORS
US6180597B1 (en) * 1998-03-19 2001-01-30 Brigham And Women's Hospital, Inc. Upregulation of Type III endothelial cell nitric oxide synthase by rho GTPase function inhibitors
WO1999047153A2 (en) * 1998-03-19 1999-09-23 Brigham & Women's Hospital, Inc. UPREGULATION OF TYPE III ENDOTHELIAL CELL NITRIC OXIDE SYNTHASE BY rho GTPase FUNCTION INHIBITORS
US6696480B2 (en) 1998-07-14 2004-02-24 Brigham And Women's Hospital, Inc. Upregulation of type III endothelial cell nitric oxide synthase by agents that disrupt actin cytoskeletal organization
US6423751B1 (en) * 1998-07-14 2002-07-23 The Brigham And Women's Hospital, Inc. Upregulation of type III endothelial cell nitric oxide synthase by agents that disrupt actin cytoskeletal organization
WO2000003746A3 (en) * 1998-07-14 2000-04-20 Brigham & Womens Hospital Upregulation of type iii endothelial cell nitric oxide synthase by agents that disrupt actin cytoskeletal organization
WO2000003746A2 (en) * 1998-07-14 2000-01-27 The Brigham And Women's Hospital, Inc. Upregulation of type iii endothelial cell nitric oxide synthase by agents that disrupt actin cytoskeletal organization
US20060020020A1 (en) * 1999-01-13 2006-01-26 Curis, Inc. Regulators of the hedgehog pathway, compositions and uses related thereto
US20040006094A1 (en) * 2000-08-08 2004-01-08 Grant Elfrida R. 4-pyrimidinamine derivatives, pharmaceutical compositions and related methods
US20030225085A1 (en) * 2000-08-08 2003-12-04 Grant Elfrida R. 2-pyridinamine compositions and related methods
US20050203092A1 (en) * 2000-08-08 2005-09-15 Benjamin Elfrida R. 4-Pyrimidinamine derivatives, pharmaceutical compositions and related methods
US20030212079A1 (en) * 2000-08-08 2003-11-13 Grant Elfrida R. 4-pyrimidinamine derivatives, pharmaceutical compositions and related methods
DE102004019413A1 (en) * 2004-04-19 2005-11-24 Phenos Gmbh Use of substances (e.g. nucleic acids, proteins and peptides), which restrain/reduce the expression and/or activity of protein kinase C-epsilon for the treatment/prevention of e.g. circulatory and vascular diseases
DE102008029072A1 (en) * 2008-06-10 2009-12-17 Lang, Florian, Prof. Dr.med. Substance, which inhibits serum and glucocorticoid dependent kinase 3, useful for the prophylaxis and/or treatment or diagnosis of age-related diseases e.g. arteriosclerosis, skin atrophy, myasthenia, infertility, stroke and kyphosis
US20150133405A1 (en) * 2012-05-08 2015-05-14 Aeromics, Llc Methods
US9573885B2 (en) 2012-05-08 2017-02-21 Aeromics, Inc. Methods of treating cerebral edema
US9994514B2 (en) * 2012-05-08 2018-06-12 Aeromics, Inc. Methods of treating cerebral edema and spinal cord edema
US11084778B2 (en) 2012-05-08 2021-08-10 Aeromics, Inc. Methods of treating cardiac edema, neuromyelitis optica, and hyponatremia
US11873266B2 (en) 2012-05-08 2024-01-16 Aeromics, Inc. Methods of treating or controlling cytotoxic cerebral edema consequent to an ischemic stroke
US9827253B2 (en) 2013-11-06 2017-11-28 Aeromics, Inc. Prodrug salts
US9949991B2 (en) 2013-11-06 2018-04-24 Aeromics, Inc. Methods of treating aquaporin-mediated conditions
US10258636B2 (en) 2013-11-06 2019-04-16 Aeromics, Inc. Prodrug salts
US10894055B2 (en) 2013-11-06 2021-01-19 Aeromics, Inc. Pharmaceutical compositions, methods of making pharmaceutical compositions, and kits comprising 2-{[3,5-bis(trifluoromethyl)phenyl]carbamoyl}4-chlorophenyl dihydrogen phosphate
US11071744B2 (en) 2013-11-06 2021-07-27 Aeromics, Inc. Prodrug salts
US11801254B2 (en) 2013-11-06 2023-10-31 Aeromics, Inc. Pharmaceutical compositions and methods of making pharmaceutical compositions comprising 2-{[3,5-bis(trifluoromethyl)phenyl]carbamoyl}-4-chlorophenyl dihydrogen phosphate

Similar Documents

Publication Publication Date Title
US5500420A (en) Metabotropic glutamate receptor agonists in the treatment of cerebral ischemia
US5519035A (en) Treatment of stroke or in anticipation of the occurrence of brain ischemia
el Nasr et al. Neuroprotective effect of memantine demonstrated in vivo and in vitro
US5334618A (en) Method of preventing NMDA receptor-mediated neuronal damage
US5614560A (en) Method of preventing NMDA receptor-mediated neuronal damage
Jin et al. Polyhydroxylated C60, fullerenols, as glutamate receptor antagonists and neuroprotective agents
Oka et al. Vulnerability of oligodendroglia to glutamate: pharmacology, mechanisms, and prevention
Solá et al. Death receptors and mitochondria: two prime triggers of neural apoptosis and differentiation
KR960008230B1 (en) Compositions for inhibition of disorders associated with oxidative damage
Richelson Lithium ion entry through the sodium channel of cultured mouse neuroblastoma cells: a biochemical study
Seo et al. Oxidative stress induced cytokine production in isolated rat pancreatic acinar cells: effects of small-molecule antioxidants
JP2002508399A (en) Agonists of metabototropic glutamate receptor and uses thereof
Gilat et al. Anticonvulsant treatment of sarin-induced seizures with nasal midazolam: an electrographic, behavioral, and histological study in freely moving rats
WO1994005275A9 (en) Method of preventing nmda receptor-mediated neuronal damage
Borges et al. Changes in brain microvessel endothelial cell monolayer permeability induced by adrenergic drugs
Cotzias Metabolic modification of some neurologic disorders
EP1372620A2 (en) Methods for restoring cognitive function following systemic stress
US5158976A (en) Controlling glutamine/glutamate related neuronal injury
SK154796A3 (en) Use of rapamycin for the inhibition of neuronal cells necrosis
Chrobak et al. Hemicholinium-3 prevents the working memory impairments and the cholinergic hypofunction induced by ethylcholine aziridinium ion (AF64A)
JPH0898679A (en) Use of interferon gamma for inhibition of growth and differentiation of primitive hemopoietic precursor cell
Zuddas et al. Acetaldehyde directly enhances MPP+ neurotoxicity and delays its elimination from the striatum
WO1992017168A1 (en) Method of preventing nmda receptor-mediated neuronal damage
Kelleher et al. Protection of astrocytes by fructose 1, 6-bisphosphate and citrate ameliorates neuronal injury under hypoxic conditions
US6362160B1 (en) Immunophilin-binding agents prevent glutamate neurotoxicity associated with vascular stroke and neurodegenerative diseases

Legal Events

Date Code Title Description
AS Assignment

Owner name: CORNELL RESEARCH FOUNDATION, INC., NEW YORK

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:MAIESE, KENNETH;WAGNER, JOHN A.;REEL/FRAME:006665/0849

Effective date: 19930720

FEPP Fee payment procedure

Free format text: PAYOR NUMBER ASSIGNED (ORIGINAL EVENT CODE: ASPN); ENTITY STATUS OF PATENT OWNER: SMALL ENTITY

REMI Maintenance fee reminder mailed
FPAY Fee payment

Year of fee payment: 4

SULP Surcharge for late payment
FPAY Fee payment

Year of fee payment: 8

REMI Maintenance fee reminder mailed
LAPS Lapse for failure to pay maintenance fees
STCH Information on status: patent discontinuation

Free format text: PATENT EXPIRED DUE TO NONPAYMENT OF MAINTENANCE FEES UNDER 37 CFR 1.362

FP Lapsed due to failure to pay maintenance fee

Effective date: 20080521